[NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THIS CONFIDENTIAL
INFORMATION. THESE PORTIONS HAVE BEEN MARKED WITH THE CLAUSE "CONFIDENTIAL
TREATMENT REQUESTED" AND/OR TWO ASTERISKS ENCLOSED IN BRACKETS (i.e., [**]). THE
CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.]
JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
This Joint Development and Commercialization Agreement ("Agreement") dated as of the 16th day of July, 2001
("Effective Date") is by and between deCODE GENETICS, ehf., an Icelandic corporation, located at
Hlioarsmari 15, 200 Kopavogur, Iceland ("deCODE"), and PE CORPORATION (NY), a New York
corporation, through its Applied Biosystems Group, located at 850 Lincoln Centre Drive, Foster City, CA
A. ABG has certain skills, proprietary technology and know-how related to the development of bioanalytical
instrumentation systems including associated software and reagents, and the marketing, sales and support of
products incorporating such systems.
B. deCODE has certain skills, proprietary technology and know-how related to the operation and management
of large scale genotyping facilities, including particular expertise in the development of software to manage and
analyze data generated by such facilities.
C. deCODE and ABG desire to form a joint development and commercialization program with the objective of
developing and commercializing software products for the collection, organization and analysis of genotyping
information subject to the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the foregoing premises and the mutual promises and covenants
contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: